TabsDetailsBasic DetailsDate Posted: Thursday, October 11, 2018Status: CompleteMedical Product: phosphodiesterase type 5 (PDE5) inhibitorDescription: The goal of this query was to estimate phosphodiesterase type 5 (PDE5) inhibitor utilization among women in the Sentinel Distributed Database (SDD). Report 1 contains estimates of phosphodiesterase type 5 (PDE5) inhibitor use among reproductive-aged women. Report 2 contains estimates of PDE5 inhibitor use that occurred during a pregnancy ending in a live-born delivery or within 90 days prior to pregnancy start, among women. Data from January 1, 2001 to March 31, 2018 from 16 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on August 27, 2018. Read More Deliverables (2)Sentinel Modular Program Report: Phosphodiesterase Type 5 (PDE5) Inhibitor Utilization Among Reproductive-Aged Women, Report 1Sentinel Modular Program Report: Phosphodiesterase Type 5 (PDE5) Inhibitor Utilization Among Pregnant Women, Report 2Additional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2001 - March 31, 2018Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: Females 15 to 50 years of ageData Sources: Sentinel Distributed Database (SDD)Related Links: 2019 ICPE Poster: Phosphodiesterase Type 5 (PDE-5) Inhibitor Use Among Pregnant Women and Women of Reproductive Age in the United StatesPhosphodiesterase Type 5 Inhibitor Use Among Pregnant and Reproductive‐Age Women in the United States
